help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology, doi:10.1210/en.2006-0500
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Ip, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Ip, M. M.
Endocrinology Vol. 148, No. 1 268-278
Copyright © 2007 by The Endocrine Society

NF{kappa}B1/p50 Is Not Required for Tumor Necrosis Factor-Stimulated Growth of Primary Mammary Epithelial Cells: Implications for NF{kappa}B2/p52 and RelB

Jiping Zhang, Mary Ann Warren, Suzanne F. Shoemaker and Margot M. Ip

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York 14263

Address all correspondence and requests for reprints to: Margot M. Ip, Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263. E-mail: Margot.Ip{at}roswellpark.org.


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Nuclear factor {kappa}B (NF{kappa}B) plays an important role in mammary gland development and breast cancer. We previously demonstrated that TNF stimulates growth of mammary epithelial cells (MEC) in a physiologically relevant three-dimensional primary culture system, accompanied by enhanced DNA-binding of the NF{kappa}B p50 homodimer. To further understand the mechanism of TNF-stimulated growth of primary MEC, the requirement for NF{kappa}B1/p50, and the role of cyclin D1 in TNF-stimulated growth were examined. TNF induced the formation of DNA-binding complexes of p50 and p52 with their coactivator bcl3 in MEC nuclear extracts. Concomitantly, TNF increased the binding of NF{kappa}B proteins to the {kappa}B site on the cyclin D1 promoter, and increased expression of cyclin D1 mRNA and protein. Using MEC from p50 null mice, we found that p50 was not required for TNF-induced growth nor for up-regulation of cyclin D1. However, TNF induced a p52/RelB NF{kappa}B DNA-binding complex in p50 null MEC nuclear extracts. In addition, we found that in wild-type MEC, TNF stimulated the occupancy of p52 and RelB on the cyclin D1 promoter {kappa}B site, whereas p50 was present constitutively. These data suggest that in wild-type MEC, TNF stimulates the interaction of bcl3 with p50 and p52, and the binding of p52, as well as RelB, to cyclin D1 promoter {kappa}B sites, and as a consequence, stimulates the growth of MEC. In the absence of p50, p52 and RelB can compensate for p50 in TNF-stimulated growth and cyclin D1 induction in MEC.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
BREAST CANCER IS the most common type of cancer in U.S. women. To gain a greater understanding of its initiation and progression, it is necessary to identify those factors that regulate the growth and differentiation of the mammary epithelium. Previous studies in our laboratory suggested that TNF is a potential regulator of normal mammary gland development (Ref. 1 ; and Varela, L., N. Stangle-Castor, S. Shoemaker, and M. Ip, unpublished observations). Normal mammary epithelial cells (MEC) express TNF protein, as well as TNF and TNF receptor mRNAs in a developmentally regulated manner (1). Moreover, in vivo studies using TNF null mice found that ductal morphogenesis of the mammary epithelium is inhibited during puberty (Stangle-Castor, N., P. A. Masso-Welch, S. F. Shoemaker, J. Zhang, M. J. Ehrke, D. Liu, and M. Ip, manuscript in preparation). In a physiologically relevant primary MEC culture model established in our laboratory (2, 3, 4), we previously demonstrated that TNF induced the growth as well as extensive branching morphogenesis of rat MEC (5, 6, 7), effects that are mediated through the p55 TNF receptor (1) and matrix metalloproteinase-9 (7). TNF was also found to inhibit functional differentiation (1, 5, 6, 8, 9). More recently, we found that, in contrast to the TNF-induced cell death or stasis in breast cancer cell lines, TNF increased the growth of mammary tumor cells derived from N-methyl-N-nitrosourea-induced rat (10) and erbB2-overexpressing mouse (Shoemaker, S., and M. Ip, unpublished observations) mammary tumors in three-dimensional primary culture. The proliferation of both normal and transformed rat MEC was accompanied by increased DNA-binding activity of the nuclear factor {kappa}B (NF{kappa}B) p50 homodimer (10).

NF{kappa}B is a pleiotropic transcription factor, controlling inflammation, cell survival, transformation, and oncogenesis (11). There are five members in the NF{kappa}B/Rel family: p65 (RelA), p50/105 (NF{kappa}B1), p52/p100 (NF{kappa}B2), c-rel, and RelB, which bind to DNA as homodimers or heterodimers. All the NF{kappa}B proteins share a 300-residue N-terminal Rel homology domain that mediates the DNA binding, dimerization, and nuclear targeting functions, as well as interaction with inhibitor of NF-{kappa}B (I{kappa}B) (11). The mature DNA-binding proteins p50 and p52 are generated by proteolytic processing of p105 and p100 precursors, respectively (12). Among the five NF{kappa}B proteins, p65, c-Rel, and RelB contain transcriptional activation domains, whereas p50 and p52 do not (12). However, a member of the I{kappa}B family, Bcl3, can function as a transcriptional coactivator for p50 and p52 homodimers (13, 14). NF{kappa}B signaling consists of both canonical and noncanonical pathways (reviewed in Refs. 11 and 15). In the canonical pathway, upon stimulation with cytokines, the I{kappa}B proteins that sequester NF{kappa}B proteins in the cytoplasm are phosphorylated by an I{kappa}B kinase (IKK) complex and rapidly degraded, releasing NF{kappa}B to translocate to the nucleus. In the noncanonical pathway, NF{kappa}B-inducing kinase (NIK) and IKK{alpha} are stimulated through receptors including the B cell-activating factor receptor (BAFF), CD40, and the lymphotoxin ß receptor, resulting in an induction of the processing of p100 to p52 and facilitating the nuclear translocation of RelB/p52 dimers into the nucleus (15). In contrast to the tight regulation of p52 processing, the proteolysis of the precursor protein p105 to p50 is constitutive in unstimulated cells (11). Several studies have demonstrated that p50 and p52, the two highly homologous NF{kappa}B subunits, have distinct but also many redundant functions in bone development and B cell differentiation (16, 17, 18, 19).

NF{kappa}B plays a key role in mammary gland development (20) and breast cancer progression (21). Abnormal proliferation and branching of the mammary epithelium is observed in mice lacking the I{kappa}B{alpha} gene (22). Elevated NF{kappa}B DNA-binding activity has been reported in both mammary carcinoma cell lines and primary breast cancer cells of human and rodent origin (23, 24, 25, 26). Moreover, interruption of NF{kappa}B activation restored the sensitivity of endocrine-resistant breast cancer to tamoxifen (27). A number of studies have been carried out to understand the contribution of different NF{kappa}B members to breast tumorigenesis (24, 28, 29). Interestingly, although p50/p65 is the major increased NF{kappa}B dimer in breast cancer cell lines, NF{kappa}B dimers composed of p50 or p52, as well as their coactivator, bcl3, are the selectively up-regulated NF{kappa}B proteins in human breast tumor tissue, suggesting a different activation pattern in human breast tumors when compared with breast cancer cell lines (24, 29). More recently, Zhou et al. (27, 30) suggested that the activity of the p50 homodimer might be used as a prognostic marker in a subset of ER-positive breast cancer patients. However, little is known about the role of p50 in regulating the growth of MEC.

In the studies reported in this article, we investigated the role of NF{kappa}B1/p50 in primary MEC, with the objective of determining whether p50 was required for TNF stimulation of growth and cyclin D1 expression. We found that TNF increased the expression of cyclin D1 in proliferative primary MEC associated with an activation of NF{kappa}B1/p50. However, NF{kappa}B1/p50 was not required for the proliferation or the up-regulation of cyclin D1 by TNF in MEC. In contrast, NF{kappa}B2/p52 and RelB appear to play important roles in TNF-stimulated, NF{kappa}B-mediated growth of primary MEC.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
Sprague Dawley CD female rats were purchased from Charles River Laboratories (Wilmington, MA). NF{kappa}B/p50 null mice (B6, 129-Nfkb1tm1Bal) or age-matched wild-type mice (B6129PF2/J) were obtained from Jackson Laboratories (Bar Harbor, ME). Mice and rats were maintained in microisolator cages in a temperature- and humidity-controlled environment with a 12-h light, 12-h dark cycle, and were given chow and water ad libitum. The care and use of the animals was in accordance with National Institutes of Health guidelines and Institute Animal Care and Use Committee regulations.

Antibodies
The following antibodies were used in these studies. Anti-p50 (sc-114X), p52 (sc-298X), p52 (sc-848X), p65 (sc-109X), c-Rel (sc-70X), Rel B (sc-226X), and anti-bcl3 (sc-185) were obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-Hsc 70 (SPA-820) and anti-p50 (KAP-TF112) were from Stressgen Biotechnologies Corp. (Victoria, British Columbia, Canada). Anti-cyclin D1 (no. 2926) was purchased from Cell Signaling Technology Inc. (Danvers, MA). Rabbit anti-p50 serum 1157 (NCI 1157) and anti-p52 serum 1495 (NCI 1495) were kindly provided by Dr. Nancy Rice and Mimi Ernst at the National Cancer Institute, or the Biological Resources Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute-Frederick Cancer Research and Development (Frederick, MD). Detection of p50 by Western blot was performed using the NCI 1157 antibody, unless specified otherwise. Horseradish peroxidase-conjugated donkey antimouse and donkey antirabbit secondary antibodies were purchased from Jackson ImmunoResearch Laboratories Inc. (West Grove, PA).

Isolation and primary culture of mammary epithelial organoids
Isolation and primary culture of mammary epithelial organoids were performed according to the protocol developed by our laboratory (31, 32). Briefly, rats at 56–66 d of age or mice at 8–10 wk of age were killed, then mammary glands were removed, minced, and digested with collagenase III (Worthington Biochemical Corp., Lakewood, NJ) at 172.8 U/ml (rat) or 108 U/ml (mouse) and with dispase (Roche Applied Science, Mannheim, Germany) at 1.2 mg/ml (rat) or 0.7 mg/ml (mouse) for 12 h to isolate mammary epithelial organoids. After enrichment (31, 32), the rat or mouse organoids were embedded within an Engelbreth-Holm-Swarm (EHS)-derived reconstituted basement membrane (RBM) [prepared from the EHS sarcoma as described previously (2, 3)] and cultured in an EGF-free serum-free medium (SFM) consisting of phenol red-free DMEM-F12 (50:50, vol:vol) with 10 µg/ml insulin, 1 µg/ml progesterone, 1 µg/ml hydrocortisone, 1 µg/ml prolactin, 5 µg/ml transferrin, 5 µM ascorbic acid, 1 mg/ml fatty acid-free BSA, and 50 µg/ml gentamycin. Recombinant human or mouse TNF (40 ng/ml) (Biosource International, Camarillo, CA) were used for TNF-treated rat or mouse MEC, respectively. Ovine prolactin (NIDDK-oPRL-21) was obtained from Dr. A. F. Parlow at the National Hormone and Pituitary Program, Harbor-UCLA Medical Center (Torrance, CA).

For EMSA and Western blot, approximately six rats were used to generate MEC organoids for each experiment. At least 12 rats were used for each DNA affinity immunoblotting (DAI) assay. In the chromatin immunoprecipitation assay (ChIP) assay, 12–16 rats were used to generate MEC organoids for each time point. For the cell growth, EMSA, and Western blot studies with p50 null and wild-type mice, 20–30 mice per group, were used for each experiment.

Morphological analysis, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide], and [3H]thymidine incorporation assays
Morphological development of the MEC organoids from p50 null or wild-type mice was photographed under the x4 objective on d 1, 4, 9, and 15 of primary culture using a Nikon FX-35A camera mounted on an Olympus CK2 inverted microscope. To evaluate growth of the epithelial organoids, MEC (5 x 105) from age-matched p50 null or wild-type mice were cultured in a 24-well plate within the EHS RBM in 1 ml SFM with or without TNF (40 ng/ml) for the times indicated. The viable cell number was measured by the MTT assay as previously described (5) and is presented as OD. For determination of [3H]thymidine incorporation, wild-type mouse MEC (5 x 105 per well of a 24-well plate) organoids were cultured with or without TNF (40 ng/ml) for 6 d and pulse labeled with [3H]thymidine (5 µCi/well) for 4 h, and [3H]thymidine incorporation was determined as described previously (6). Counts per minute data were normalized to cell number using the MTT assay.

Cytosolic and nuclear extraction
Cellular fractionation was performed according to Brasier et al. (33) with modification. MEC were isolated from the EHS RBM after incubation with 5 U/ml dispase (BD Biosciences, Franklin Lakes, NJ) in Hanks’ balanced salt solution for 1 h at 37 C, and washing with cold Hanks’ balanced salt solution. Cell pellets were resuspended in buffer A [50 mM HEPES, pH 7.4, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol (DTT), 0.1 µg/ml phenylmethylsulfonyl fluoride (PMSF), 1 µg/ml pepstatin A, 1 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 10 µg/ml aprotinin, and 0.5% Nonidet P-40]. After 10 min on ice, the samples were sheared 10 times through a 22-gauge needle and centrifuged at 500 x g for 4 min at 4 C. The supernate was further centrifuged at 100,000 x g for 1 h at 4 C, and the clear fraction was saved for the cytosolic extract. The nuclear pellet was resuspended in buffer B (buffer A with 1 M sucrose) and centrifuged at 14,000 x g for 30 min at 4 C. The nuclei were purified by washing twice with cold PBS with 1 mM DTT and then incubated in buffer C (10% glycerol, 50 mM HEPES, pH 7.4, 400 mM KCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 µg/ml PMSF, 1 µg/ml pepstatin A, 1 µg/ml leupeptin, 10 µg/ml soybean trypsin inhibitor, 10 µg/ml aprotinin) with vigorous vortexing for 30 min at 4 C. After centrifugation at 14,000 x g for 10 min at 4 C, the supernate was collected as nuclear extract. As determined by immunoblotting with anti-lactate dehydrogenase (Fitzgerald Industries International Inc., Concord, MA) or anti-lamin B (Santa Cruz Biotechnology, Inc.), no cross-contamination was seen between cytosolic or nuclear fractions (data not shown).

Western blot
Twenty to 50 µg of protein were separated on 10% SDS-PAGE gels, transferred to PVDF membranes, and blotted with a 1:200 dilution of anti-bcl3 or a 1:1000 dilution of anti-p50, p52, or cyclin D1. The washed membranes were then incubated with horseradish peroxidase-conjugated donkey antirabbit or donkey antimouse antiserum (1:5000 dilution). Immunoreactive bands were visualized using the enhanced chemiluminescence detection system (Amersham Bioscience, Piscataway, NJ). The membranes were then stripped and reprobed with anti-Hsc 70 for an internal control. The density of each band was first normalized to that of the internal control and then fold inductions were determined as the ratio of relative intensities of TNF-treated vs. control samples.

Isolation of RNA and Northern blot
To isolate RNA from primary cultured MEC, media were removed from the 100-mm culture dishes and 3 ml TRIzol reagent (Life Technologies, Grand Island, NY) was added to each dish. Total RNA was isolated according to the manufacturer’s protocol. Northern blot was performed as previously described (8). The density of cyclin D1 mRNA was first normalized by that of the internal control glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and then fold inductions were determined as the ratio of relative intensities of TNF-treated vs. control samples. The plasmid containing cyclin D1 cDNA was kindly provided by Dr. Yan Dong (Roswell Park Cancer Institute, Buffalo, NY). The recombinant human GAPDH cDNA probe was purchased from Clontech (Palo Alto, CA).

DAI assay
The DAI assay was performed according to Liu et al. (34). In brief, 200 µg cytosolic or nuclear protein from control or TNF-treated MEC was incubated with 5' end-labeled biotin-consensus NF{kappa}B oligo (5'-AGTTGAGGGGACTTTCCCAGGC-3') (Integrated DNA Technologies, Coralville, IA) at 4 C for 30 min. Biotin-NF{kappa}B oligo/protein complexes were captured by incubation with streptavidin magnetic beads (Promega Corp., Madison, WI). The beads were pelleted by a strong magnet and the protein complex was eluted using 2x SDS sample loading buffer and resolved on SDS-PAGE. The proteins bound to the NF{kappa}B oligo were detected by Western blot using specific antibodies as indicated.

EMSA
EMSA was performed as described previously (10) except that 10 µg nuclear protein was used for each reaction and antibodies were incubated at 4 C overnight for the supershift analyses. NF{kappa}B oligonucleotide containing consensus NF{kappa}B binding site (5'-AGTTGAGGGGACTTTCCCAGGC-3') and mutant NF{kappa}B oligo (5'-AGTTGAGGCGACTTTCCCAGGC-3') were ordered from Santa Cruz Biotechnology, Inc. NF{kappa}B oligonucleotide containing the {kappa}B site on the rat cyclin D1 promoter (5'-ACTACAGGGGAGTTTTGTTG-3') was purchased from Integrated DNA Technologies.

ChIP
The ChIP protocol was adapted from previous reports (35, 36) with modifications. After culturing MEC organoids in SFM for 5 d, cells were treated with or without TNF (40 ng/ml) for the times indicated. MECs were then isolated from the EHS RBM and fixed with 1% formaldehyde at room temperature for 10 min. Cross-linking was stopped by the addition of glycine to a final concentration of 125 mM for 5 min. Fixed MECs were washed in cold PBS. Pellets from approximately 108 cells were resuspended in 2 ml cell lysis buffer [5 mM piperazine-N,N'-bis(2-ethanesulfonic acid), pH 8.0, 85 mM KCl, 0.5% NP-40, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 mM PMSF] and incubated on ice for 10 min. Cell membranes were broken by shearing the MEC suspension 10 times through a 22-gauge needle. Nuclei were pelleted by centrifugation at 2000 x g for 5 min. Using nuclei counts to estimate cell number, nuclear pellets from control or TNF-treated groups were resuspended in nuclei lysis buffer [50 mM Tris-HCl (pH 8.1), 10 mM EDTA, 1% SDS with the same protease inhibitors as in the cell lysis buffer] to the same final concentration of approximately 2 x 108 per ml and incubated on ice for 10 min. Chromatin was sheared to an average length of 100- to 400-bp DNA fragments by sonication of the nuclear lysate on ice for 25 10-sec pulses using the Sonic Dismembrator (Fisher Model 60, Pittsburgh, PA) at a power setting of 2–3. Debris was cleared by centrifugation at 14,000 x g for 15 min at 4 C. A part of the sonicated lysate from each time point (50–100 µl) was saved to use for input control. The lysate from 2 x 108 MEC was diluted 10-fold with ChIP dilution buffer [0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl (pH 8.1), 167 mM NaCl with the same protease inhibitors as in cell lysis buffer] and precleared with 80 µl of salmon sperm DNA/protein A agarose (Upstate Cell Signaling Solutions, Lake Placid, NY) for 30 min at 4 C followed by centrifugation at 500 x g for 5 min. Aliquots of precleared lysate were incubated with 10 µg of anti-p50 (sc-114X), anti-p52 (sc-848X), anti-RelB (sc-226X), or rabbit IgG for 16 h at 4 C before the addition of 60 µl of salmon sperm DNA/protein A agarose beads for another 4-h incubation to collect the antibody/NF{kappa}B protein complex. The agarose beads were centrifuged at 500 x g for 5 min and washed sequentially with Low Salt, High Salt, LiCl Immune Complex Wash Buffer and TE buffer as described in the protocol provided with the beads. Cross-linked DNA-protein complexes were eluted from the beads by adding 250 µl of freshly prepared elution buffer (1% SDS, 0.1 M NaHCO3), vortexing, then incubating the complexes at room temperature for 15 min with rotation. Elution was repeated with another 250 µl of elution buffer and both eluates were combined. The DNA-protein cross-link was reversed by incubating the above eluent or input lysate first with 40 µg/ml RNase and 200 mM NaCl at 65 C for 16 h and then with 10 mM EDTA, 40 mM Tris-HCl, and 160 µg/ml of protease K at 45 C for 1 h. DNA was extracted with phenol-chloroform-isoamyl alcohol (25:24:1, vol:vol:vol) and then precipitated with 1/10 volume of 3 M NaOAc (pH 5.3), 20 µg glycogen, and 2.5 volumes of EtOH at –80 C overnight. DNA was collected by centrifugation at 14,000 x g for 30 min at 4 C and resuspended in 30 µl of H2O. Input samples were diluted 50-fold before PCR. Each PCR mixture contained 1 µl of immunoprecipitate or diluted input sample, 1x PCR buffer (Roche Applied Science), 200 µM dNTP (Roche Applied Science), and 1 U Taq DNA polymerase (Roche Applied Science) in a total volume of 50 µl. PCRs were performed by denaturing at 94 C for 20 sec, annealing at 59 C ({kappa}B site) or 55 C (non-{kappa}B site) for 30 sec, and extending at 72 C for 1 min for 35 cycles. Half of each PCR product was electrophoresed on a 2% agarose gel and visualized using ethidium bromide. The primers that specifically amplify a 105-bp DNA fragment containing the {kappa}B site on the rat cyclin D1 promoter were 5'-CTC CTT TTT CTC TGC CCG GCT T-3' (sense) and 5'-CCC TCT GGA GGC TGC AGG ACT T-3' (antisense). The primers that amplify a 146-bp DNA fragment without a {kappa}B site on the rat cyclin D1 promoter were 5'-CAA CGA AGC CAA TCG GGA AG-3' (sense) and 5'-GAG AAA AAT AAA TCT TTG AAG-3' (antisense).

Statistics
The MTT data were analyzed by one way ANOVA at each time point, using the Holm-Sidak method for pairwise multiple comparison. A P value of less than 0.05 was considered statistically significant. [3H]Thymidine incorporation between control and TNF-treated groups was analyzed using Student’s t test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Characterization of TNF-induced NF{kappa}B-DNA binding complexes in rat MEC in primary culture
Our laboratory previously reported that TNF increases the proliferation of rat MEC in primary culture associated with an increase in the DNA-binding activity of the NF{kappa}B1/p50 homodimer (10). To further understand the role of p50 in regulating the growth of MEC, we used antibodies against all five members of the NF{kappa}B family to examine the composition of consensus NF{kappa}B DNA-binding complexes in the nuclear extracts of rat MEC treated with or without 40 ng/ml TNF. We chose this TNF concentration in all of our present studies because it was shown previously to modify MEC growth and differentiation, whereas higher levels of TNF did not have additional effects (5). Using EMSA, two TNF-stimulated NF{kappa}B-binding complexes were detected in rat MEC nuclear extracts, a minor slower migrating band (labeled complex 1), and a major band (labeled complex 2), which migrated with higher mobility (Fig. 1Go). The majority of complex 1, and all of complex 2 were depleted by the p50 antibody (sc-114x), leading to the formation of two supershift bands. Complex 1 was also depleted by the p65 antibody, suggesting that this minor DNA-binding complex contained the p65/p50 heterodimer. Additionally, two supershift bands were detected with the p52 antibody (NCI 1495), concomitant with a slight decrease in the intensity of the upper band; together with partial depletion of the upper band with the RelB antibody, this suggests that the complexes that comprise the upper band may also include p52 and RelB. Therefore, these data demonstrate that, although the major NF{kappa}B-DNA binding complex in rat MEC in primary culture is composed of a p50/p50 homodimer, additional complexes of p65/p50, as well as complexes containing p52 and RelB are also present and induced by TNF.


Figure 1
View larger version (123K):
[in this window]
[in a new window]

  		FIG. 1. Characterization of the TNF-induced NF{kappa}B DNA binding complexes in primary rat MEC. MEC were cultured in the absence (control, C) or presence of TNF for 10 d, and nuclear extracts were prepared for EMSA. Two TNF-inducible NF{kappa}B DNA binding complexes were detected in rat MEC (arrows); a minor complex is denoted as 1, and a major complex is denoted as 2. In supershift analysis using the samples from the TNF-treated cells (lanes 3–7), subsequent to the incubation of nuclear extract with 32P-labeled NF{kappa}B oligo, antibodies against the different NF{kappa}B subunits, p50 (sc-114X), p52 (NCI 1495), p65, c-Rel, and RelB, were added to the reaction mixture for further incubation before loading. M, Competition of nuclear extracts from TNF-treated MEC with cold mutant NF{kappa}B oligo. Cold, competition of nuclear extracts from TNF-treated MEC with cold consensus NF{kappa}B oligo. The asterisk indicates free probe. The results are representative of two independent experiments using this p52 antibody, and of more than three independent experiments using each of the other antibodies.

 
To understand the mechanism by which the NF{kappa}B-DNA binding activity was increased, Western blot analysis was used to determine whether TNF altered the expression or nuclear translocation of p50 and its coactivator bcl3. p52 was also examined because of its close homology to p50. The expression of p50 was increased modestly by TNF in both cellular fractions on d 3 and 8, and more extensively on d 12 (Fig. 2AGo). In addition to the 50-kDa p50 band, one to three bands varying from 51–55 kDa were seen in both cellular fractions although this heterogeneity was more pronounced in the nuclear fraction. The characteristics of these more slowly migrating proteins are not known, but they may represent phosphorylated species. Interestingly, p105, the precursor of p50, was found in the nucleus as well as the cytoplasm, although the difference in mobility (cytoplasmic p105 migrated more slowly) suggests a difference in their posttranslational modification. TNF did not have a major effect on the levels of p105, although the expression of the slower migrating form of p105 was increased in the nucleus at both d 8 and 12, and the more rapid form at d 12 in the TNF groups. The presence of p105 in the nucleus, as well as the TNF-induced increase in a putative posttranslationally modified species, raises the possibility that nuclear p50/p105 complexes may form and be biologically significant.


Figure 2
View larger version (66K):
[in this window]
[in a new window]

  		FIG. 2. Effect of TNF on the expression, localization, and interaction of p50 and p52 with their coactivator bcl3 in rat MEC in primary culture. A, Expression of p50, p52, and bcl3 proteins in cytosolic (C) and nuclear extracts (N) of rat MEC cultured with or without TNF for 3, 8, or 12 d was determined by Western blot. Twenty micrograms of protein were loaded in each lane. Hsc 70 was used as a loading control. B, Identification and localization of proteins bound to the NF{kappa}B consensus oligo in MEC (DAI assay). Proteins binding to the biotinylated NF{kappa}B oligonucleotide in cytosolic or nuclear extracts of MEC (200 µg protein per sample) were pulled down by streptavidin magnetic beads and analyzed by Western blot. A and B, The membranes were blotted sequentially with antibodies to bcl3, p50 (KAP-TF112), and p52 (sc-298X). Proteins of interest are indicated by arrows. The results are representative of three independent experiments.

 
Similar to p50, the expression of p52 and p100 was increased by TNF in MEC, although this increase was most dramatic in the cytosolic fraction and only p100 was increased in the nucleus (Fig. 2AGo). Finally, we found bcl3 in both cytoplasmic and nuclear fractions of rat MEC, and moreover, it was TNF-inducible at later time points in culture (Fig. 2AGo). Bcl3 migrated as a heterogeneous set of one to four bands of 60–77 kDa with distinct patterns noted between cytoplasmic and nuclear fractions.

Because bcl3 has previously been shown to be required for transactivation of the p50 and p52 homodimers (13, 37), we next investigated the effect of TNF on the interaction of p50 and p52 with bcl3 using the DAI assay (Fig. 2BGo). This assay allows detection of proteins that bind to the NF{kappa}B oligo (e.g. p50, p52, or their precursors), as well as proteins such as bcl3, which form complexes with NF{kappa}B family members. After immunoblotting proteins bound to the biotin-labeled NF{kappa}B oligo, we found that TNF induced nuclear NF{kappa}B-DNA binding complexes containing p50, p52, p105, and/or p100. Bcl3 was found to be associated with these nuclear DNA-binding complexes. TNF also increased the DNA-binding activity of cytoplasmic p50 and p100. Together, these data show the existence of TNF-inducible DNA-binding complexes composed of bcl3 with p50 and/or p52 in this physiological MEC model system. The data also suggest the possibility that bcl3 may interact with p105 or p100 in a DNA-binding complex, although to our knowledge this has not previously been described.

NF{kappa}B1/p50 is not required for TNF-stimulated growth or morphogenesis of MEC
Our previous studies (10), together with Figs. 1Go and 2Go, suggested that p50 might play an important role in the stimulation of MEC growth by TNF. To determine whether p50 is required, we compared the effect of TNF on the growth and morphogenesis of freshly isolated MEC from p50 null and wild-type mice. For each p50 null mouse used in the assays, the genotype was verified (16); we also confirmed their inability to synthesize the p50 protein. As shown in Fig. 3Go, no p50 or p105 was detected in the whole cell lysate of p50 null mammary glands or in cultured MEC using the p50 antibody NCI 1157. Figure 3Go also shows that total cellular levels of p50 and p105 in wild-type mouse MEC do not change after 4 or 8 d of TNF treatment. In a separate experiment, TNF did not alter nuclear or cytoplasmic levels of p50 or p105 in wild-type mouse MEC (evaluated on d 8; data not shown). Importantly, we found that TNF significantly increased the growth of MEC from both wild-type and p50 null MEC to a similar extent (~2.8-fold on d 15) (Fig. 4Go). This increase in cell number resulted, at least in part, from an increase in DNA synthesis, because in an experiment with wild-type MEC, [3H]thymidine incorporation was increased 7-fold (P < 0.001) by TNF (data not shown). Additionally, MEC from the wild-type and p50 null groups grew from end-bud-like organoids to multilobular alveolar colonies, and this morphological development was stimulated by TNF to a similar extent in both groups (Fig. 5Go). However, in contrast to rat MEC (10), no ductal branching morphogenesis was observed in TNF-treated mouse MEC. From the data in Figs. 4Go and 5Go, we conclude that p50 is not required for TNF-stimulated growth or morphogenesis of MEC.


Figure 3
View larger version (47K):
[in this window]
[in a new window]

  		FIG. 3. Confirmation that mammary glands and MEC from p50 null mice do not express NF{kappa}B1/p50. NF{kappa}B1/p50 was detected by Western blot using the NCI 1157 antibody in the whole cell lysates of mammary gland tissue (A) and MEC cultured with or without TNF (B). Arrows indicate the positions of p50 and its precursor p105. The same blots were stripped and reblotted with anti-Hsc 70 as a loading control. The results are representative of at least two independent experiments.

 

Figure 4
View larger version (24K):
[in this window]
[in a new window]

  		FIG. 4. TNF increases viable cell number of p50 null and wild-type mouse MEC grown in primary culture. The viable cell number of control or TNF-treated (40 ng/ml) MECs from p50 null (KO) or wild-type (WT) mice was determined by MTT assay, and is presented as OD from that assay. The OD reading shown in the graph is the mean of triplicate samples for each time point (±SEM). TNF-stimulated growth is significantly increased on d 12 and 15 in both wild-type and p50 null groups, and is significantly increased on d 8 in the p50 null group. This result is representative of two independent experiments.

 

Figure 5
View larger version (118K):
[in this window]
[in a new window]

  		FIG. 5. Wild-type and p50 null MEC organoids underwent similar morphological development in primary culture in the absence or presence of TNF. Mouse MEC organoids grew from simple end-bud-like organoids (arrowheads) to multilobular alveolar organoid colonies (arrows). This figure is representative of three independent experiments.

 
NF{kappa}B2/p52 and RelB may compensate for p50 in p50 null mice
To clarify the mechanism by which TNF stimulated the growth of MEC in the absence of p50, we used EMSA to compare the consensus NF{kappa}B DNA-binding activity in cultured MEC nuclear extracts from p50 null and wild-type mice after 6 d of treatment with or without TNF. As seen in Fig. 6AGo, two TNF-stimulated DNA-binding complexes were detected in wild-type MEC; in contrast, only a single complex was detected in p50 null MEC, which migrated at the same position as the upper band (complex 1) in wild-type nuclear extracts.


Figure 6
View larger version (47K):
[in this window]
[in a new window]

  		FIG. 6. Identification of NF{kappa}B DNA-binding complexes in wild-type and p50 null mouse MEC. MEC were grown in primary culture with or without TNF (40 ng/ml) for 6 d before the nuclear extracts were harvested for EMSA. A, The DNA-binding activity of consensus NF{kappa}B oligo was compared between wild-type and p50 null mice MEC. The arrows indicate two NF{kappa}B DNA-binding complexes, 1 and 2, detected in wild-type MEC. Only complex 1 was detected in p50 null MEC. B, Competition and supershift analysis using the nuclear extracts of TNF-treated MEC from wild-type or p50 null mice. The competition experiment was performed by preincubating nuclear extract (lane 1) with a 100-fold excess of unlabeled consensus (cold, lane 2) or mutant (M) (lane 3) NF{kappa}B oligo before the addition of the 32P-labeled NF{kappa}B oligo. Antibodies against p65, p50 (sc-114X), p52 (sc-848X), and RelB were used for supershift analysis. A nonspecific supershift band detected with the p50 antibody (sc-114X) is labeled (*) in the p50 null group (lane 5, see text for more details). C, Supershift analysis of NF{kappa}B2/p52. Two different p52 antibodies were incubated with TNF-treated (lanes 1–3) or untreated (lanes 4–6) nuclear extracts from wild-type or p50 null mice in supershift analysis. This experiment is representative of two independent experiments.

 
Using antibodies against NF{kappa}B p65, p50 (sc-114X), p52 (sc-848X), and RelB, supershift analysis was performed to characterize the composition of the NF{kappa}B DNA-binding complexes in the nuclear extracts of TNF-treated MEC from both groups (Fig. 6BGo). In wild-type MEC, incubation with anti-p65 depleted complex 1, whereas incubation with anti-p50 decreased the intensity of complex 1 and depleted complex 2. A modest decrease in complex 1 was seen with the p52 and RelB antibodies. These data suggest that the majority of complex 1 in wild-type MEC is composed of the p50/p65 heterodimer, and that complex 2 is the p50 homodimer. In contrast, in p50 null MEC nuclear extracts, complex 1, the sole NF{kappa}B DNA-binding species, was not shifted or decreased in intensity by the p65 antibody, but was completely depleted with anti-p52 (sc-848X) (lower panel of Fig. 6BGo, lane 6). The density of the NF{kappa}B DNA-binding complex in p50 null mice was also partially decreased by the RelB antibody (Fig. 6BGo, p50 null, lane 7). These data suggest that complex 1 in p50 null mice may contain both a p52 homodimer and a p52/RelB heterodimer.

The apparent supershift with the p50 antibody in the p50 null extracts (lower panel of Fig. 6BGo, lane 5, asterisk) is nonspecific. Indeed, while undertaking this study, we found that the sc-114X p50 antibody, in addition to detecting p50 in wild-type MEC, also detected a protein of 52–53 kDa in both wild-type and p50 null nuclear extracts (data not shown; see also Ref. 38). This suggests that this antibody may cross-react with p52, a supposition supported by the ability of the p52 antibody to supershift complex 1 in the p50 null mice. We used sc-114X anti-p50 in our supershift studies because among the p50 antibodies we have tested, it is the only commercially available antibody that can supershift p50 in the EMSA. It is important to note that, although this antibody is not specific for p50, the absence of the complex 2 NF{kappa}B DNA-binding species in p50 null mice confirms that complex 2 in wild-type MEC consists of the p50 homodimer.

To confirm our finding that p52 was present in the NF{kappa}B-DNA binding complex in p50 null MEC, we used another anti-p52 serum (NCI 1495) for supershift analysis in TNF-treated wild-type and control p50 null MEC nuclear extracts (Fig. 6CGo). The specificity of NCI 1495 to detect p52 was first tested by Western blot using whole cell lysates from p52 null and wild-type mouse embryonic fibroblasts, as well as liver and spleen from a p52 null mouse (data not shown). Consistent with the sc-848X-p52 antibody, incubation with the NCI 1495 p52 antibody abolished the NF{kappa}B DNA-binding complex 1 in the p50 null MEC nuclear extract with the exception that two supershift bands were detected (Fig. 6CGo, lane 6, arrowheads). These supershift bands were also seen in the wild-type MEC EMSA when probed with the NCI 1495 antibody (Fig. 6CGo, lane 3), although not with the sc-848X antibody (Fig. 6CGo, lane 2). Both sc-848X and NCI 1495 decreased the density of complex 1 in wild-type MEC. Figure 6CGo confirms the data of Fig. 6BGo in that the sole NF{kappa}B DNA-binding complex detected in p50 null mouse MEC (complex 1) was primarily composed of p52. It also suggests that in addition to p50/65 and p50/p50 dimers, a p52-containing NF{kappa}B complex may also be present in wild-type MEC.

To determine whether the increased DNA-binding activity of p52 was due to increased expression of p52 protein, we used Western blot to detect the level of p52 in whole cell lysates of cultured MEC from both groups treated with or without TNF. As shown in Fig. 7Go, by immunoblotting with two different p52 antibodies, we found that TNF increased the levels of p52 protein in both p50 null and wild-type MEC to a similar extent.


Figure 7
View larger version (51K):
[in this window]
[in a new window]

  		FIG. 7. TNF increases the expression of NF{kappa}B2/p52 protein in p50 null and wild-type mouse MEC. Whole cell lysates were harvested from primary MEC cultured with or without TNF at the times indicated. p52 levels were detected by Western blot using two different p52 antibodies as indicated. Arrows show the positions of the precursor p100 and p52. The same blot was stripped and reprobed with anti-Hsc 70 for loading control. This result is representative of two independent experiments.

 
Effect of TNF on NF{kappa}B-mediated expression of cyclin D1 in MEC primary culture
The TNF-stimulated growth of MEC, in association with activation of the DNA-binding activity of the p50 homodimer in wild-type MEC, and the p52/RelB heterodimer in p50 null MEC, suggested that NF{kappa}B-mediated gene transcription was important in MEC growth. Because cyclin D1 is a direct transcriptional target of NF{kappa}B (39, 40, 41), we undertook a study to determine whether TNF-stimulated growth was associated with increased cyclin D1 expression, and if so, to determine which NF{kappa}B proteins were recruited to the cyclin D1 promoter in response to TNF treatment. MEC isolated from the rat mammary gland were used for these studies to ensure adequate sample size. We initially determined the time-dependent effect of TNF on the expression of cyclin D1 mRNA and protein in MEC in primary culture. TNF increased both cyclin D1 mRNA (Fig. 8AGo) and protein (Fig. 8BGo) expression, but not until after 2 d of culture (Fig. 8Go). No significant change was detected at times less than 24 h (data not shown).


Figure 8
View larger version (46K):
[in this window]
[in a new window]

  		FIG. 8. TNF increased the expression of cyclin D1 mRNA and protein in rat MEC. Fold induction of TNF vs. control (T/C) for each time point is shown under each figure. A, Cyclin D1 mRNA (Northern blot). GAPDH was used as the RNA loading control on the same blot. B, Cyclin D1 protein (Western blot). Hsc 70 was used as the protein loading control on the same blot. This result is representative of at least two independent experiments.

 
To determine whether the up-regulation of cyclin D1 by TNF is mediated by activation of NF{kappa}B, the DNA-binding activity of NF{kappa}B to the {kappa}B site on the rat cyclin D1 promoter was examined. This NF{kappa}B binding site is conserved among human, mouse, and rat cyclin D1 promoters (40, 42, 43). Figure 9Go shows that two NF{kappa}B DNA-binding complexes were detected on the {kappa}B site of the cyclin D1 promoter, and both were TNF-inducible after 4 and 8 d of culture (Fig. 9Go, lanes 1–4). Supershift analysis performed on the nuclear extract from TNF-treated MEC showed that the major complex formed with the cyclin D1 oligo was the p50/p50 homodimer (complex 2) (Fig. 9Go, lane 7). The minor complex (complex 1) appeared to consist of the p50/p65, p50/RelB, and p52/RelB heterodimers.


Figure 9
View larger version (62K):
[in this window]
[in a new window]

  		FIG. 9. TNF induced the DNA-binding activity of the NF{kappa}B oligo containing the {kappa}B site on the cyclin D1 promoter in rat MEC. EMSA was carried out with the nuclear extract from rat MEC treated with or without TNF for 4 or 8 d. Arrows point to two NF{kappa}B DNA-binding complexes on the {kappa}B site of the cyclin D1 promoter. Competition (lane 5) and supershift analysis (lane 6–9) were performed with nuclear extract from TNF-treated MEC (d 8). The supershift band detected with the p50 antibody (sc-114X) is indicated by an arrowhead. The p52 antibody used in lane 8 was sc-848X.

 
Because the major NF{kappa}B protein bound to the cyclin D1 {kappa}B site-containing oligo is p50, we next asked whether TNF stimulated cyclin D1 expression in p50 null mouse MEC. This was found to be the case. Thus, as seen in Fig. 10Go, cyclin D1 protein levels were increased in whole cell lysates prepared from both wild-type and p50 null MEC treated with TNF, demonstrating that p50 is not required for TNF induction of cyclin D1.


Figure 10
View larger version (29K):
[in this window]
[in a new window]

  		FIG. 10. TNF induces expression of cyclin D1 protein in MEC from p50 null and wild-type mice. MEC isolated from p50 null or wild-type mice were cultured with or without TNF at the times indicated. Cyclin D1 protein was detected in whole cell lysates of MEC by Western blot. Fold induction of TNF vs. control (T/C) for each time point is shown under the figure. The loading of protein was normalized by the amount of Hsc 70 on the same blot. This result is representative of at least two independent experiments.

 
To further understand why p50 is not required in TNF-up-regulated cyclin D1 transcription and to determine whether other NF{kappa}B proteins are involved, the ChIP assay was used to examine the effect of TNF on the occupancy of different subunits of NF{kappa}B on the {kappa}B site of the rat cyclin D1 promoter in intact rat MEC. Figure 11Go shows that, although the {kappa}B site was occupied by NF{kappa}B1/p50 on d 3 and 7 of MEC primary culture, the addition of TNF did not change the amount of p50 bound to the {kappa}B site. A similar result was seen at earlier time points including 15 and 48 h (data not shown). We next determined whether p52, RelB, or p65 bound to the {kappa}B site. Similar to p50, p65 also bound to the cyclin D1 {kappa}B site, and its levels were not changed by TNF in rat MEC (Fig. 11Go). In contrast, TNF induced the binding of p52 to the same {kappa}B site at both 3 and 7 d of culture. Binding of RelB was also detected on d 7 of TNF treatment (d 3 was not tested; Fig. 11Go). The specificity of the ChIP assay was monitored in immunoprecipitated samples using two negative controls, rabbit IgG, and a non-{kappa}B site DNA fragment on the rat cyclin D1 promoter as shown in Fig. 11Go.


Figure 11
View larger version (38K):
[in this window]
[in a new window]

  		FIG. 11. The binding of p52 and RelB to the cyclin D1 promoter, but not that of p50 or p65, was induced by TNF in rat MEC in primary culture. Rat MEC were cultured with or without TNF for 3 or 7 d before cross-linking. The binding of NF{kappa}B p50, p52, RelB, and p65 to the {kappa}B site on the rat cyclin D1 promoter was determined by the ChIP assay. Antibodies against p50 or p52 were sc-114X or sc-848X, respectively. This result is representative of two separate experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
TNF is one of the important cytokines that regulate the development of the mammary gland (1). In a physiologically relevant primary MEC model (2, 3, 4), TNF was shown to increase proliferation and branching morphogenesis, and inhibit the functional differentiation of MEC (1, 5, 6, 7, 8, 9). Following our previous report that TNF-stimulated proliferation of MEC is associated with the activation of the NF{kappa}B p50 homodimer (10), we extend this in the present study to demonstrate that TNF induces nuclear DNA-binding complexes of both NF{kappa}B1/p50 and NF{kappa}B2/p52, and that these active complexes are associated with their coactivator bcl3. TNF-stimulated growth of MEC was also shown to correlate with the up-regulation of cyclin D1 and the DNA-binding of NF{kappa}B on the cyclin D1 promoter. Importantly, however, in contrast to our initial hypothesis, p50 was not required for either TNF-stimulated growth or up-regulation of cyclin D1 in MEC. Instead, our data strongly suggest that p52 and RelB compensate for p50 in the growth of MEC when p50 is absent, and that, in wild-type MEC, the TNF-stimulated up-regulation of cyclin D1 is mediated through the transactivation of both p50 and p52/RelB.

TNF stimulates DNA-binding activity of p50 and p52, and their interaction with bcl3 in MEC
Previous studies demonstrated that the activation and translocation of p50-containing NF{kappa}B dimers is regulated through cytokines such as TNF and activation of the IKK complex (canonical pathway), whereas p52-containing NF{kappa}B dimers are regulated through ligands for receptors such as CD40 and activation of NF{kappa}B-inducing kinase and IKK{alpha} (noncanonical pathway) (15). In MEC, TNF modestly increased the levels of nuclear NF{kappa}B1/p50 protein and induced its binding to 20- to 22-bp oligonucleotides containing a consensus NF{kappa}B site or the {kappa}B site on the cyclin D1 promoter. TNF also increased expression of p52 and its precursor p100 in MEC cytoplasmic fractions, as well as the expression of p100 in the nucleus. Unexpectedly, however, nuclear p52 levels were not increased by TNF, even though TNF increased binding of p52 to the biotinylated NF{kappa}B consensus oligonucleotide in the cell-free DAI assay, and to the {kappa}B site of the cyclin D1 promoter in the intact cell ChIP assay. This apparent discrepancy may reflect an activation of the DNA-binding activity of p52 by TNF, although the mechanism of this effect remains to be determined.

Our DAI data also demonstrated that TNF stimulated the DNA-binding activity of both p105 and p100. The significance of this observation is not known; however, binding complexes containing these precursors may exclude certain NF{kappa}B dimers from {kappa}B binding sites, as has been shown for RelB (44, 45) and/or affect the transcriptional activity of the complexes. With respect to the former, it is tempting to speculate that the marked induction of p100 by TNF may play a role in the virtual exclusion of the canonical p65/p50 heterodimer from {kappa}B binding sites in rat MEC. Dejardin et al. (29) previously demonstrated a physical interaction between p65 and p100. Finally, the TNF induction of p100 and its processing to p52 suggests a role for the noncanonical pathway of NF{kappa}B activation in response to TNF treatment of MEC, as has been reported in other cell types (44, 45).

Bcl3 was previously shown to specifically interact with and transactivate p50 or p52 homodimers in the nucleus (13, 14). Its expression has been documented in breast tumors but not in adjacent tissues (24), although its presence is controversial in breast cancer cell lines (24, 46). Importantly, our data show for the first time that bcl3 is expressed in normal MEC and that it is localized to both the cytoplasm and the nucleus. Moreover, TNF-inducible DNA-binding complexes of bcl3 with activated p50 and p52 were found in the nuclei of proliferating MEC. Bcl3 was detected as heterogeneous bands in MEC nuclear extracts, suggesting the presence of different phosphorylated forms of bcl3 as shown in human HepG2 cells (47). Our data suggest that bcl3 acts as a coactivator of p50 and p52 NF{kappa}B complexes in MEC although the overall transcriptional effects may depend on the relative ratio of phosphorylated bcl3 to p52 (48).

NF{kappa}B1/p50 is not required for TNF-stimulated growth of MEC nor for NF{kappa}B-mediated cyclin D1 up-regulation: roles for p52 and RelB
The studies reported in this article do not support our initial hypothesis that NF{kappa}B1/p50 is required for TNF-stimulated growth or up-regulation of cyclin D1 in MEC primary culture. Using MEC organoids from p50 null and wild-type mice, we found that TNF stimulated their growth and morphological development to a similar extent. Moreover, cyclin D1 expression was increased by TNF in both p50 null and wild-type MEC.

Although a number of genes undoubtedly contribute to the TNF-induced growth response, we chose cyclin D1 for investigation because of its regulation by NF{kappa}B and its critical role in mammary gland development (49, 50). NF{kappa}B-mediated cyclin D1 transcription contributes to cell cycle progression in mouse mammary carcinoma cells (40) and immortalized human breast epithelial cells (41). In primary cultured MEC, we showed that TNF induces the expression of cyclin D1 at both mRNA and protein levels suggesting the importance of cyclin D1 in regulating TNF-stimulated proliferation of primary MEC. The role of NF{kappa}B in cyclin D1 expression was determined using EMSA cell-free and ChIP intact cell assays to examine the effect of TNF-induced occupancy of the {kappa}B site on the cyclin D1 promoter by NF{kappa}B. In previous studies using nuclear extracts of serum-stimulated NIH3T3 cells, both the p50/p65 heterodimer and the p50 homodimer were detected on the {kappa}B site of this promoter (39, 42). Using EMSA, we detected TNF-stimulated binding of both dimers to this promoter in MEC nuclear extracts, although significantly more p50 homodimer bound than the p65/p50 heterodimer. With the more physiological ChIP assay, we discovered that the p50 occupancy of the cyclin D1 {kappa}B site was constitutive at all time points (15, 48, 72 h and d 7) tested, and was not changed after TNF treatment. In contrast, TNF markedly stimulated the binding of both p52 and RelB to the {kappa}B site on the promoter. Together, these data suggest that: 1) cyclin D1 is important in the proliferation of MEC in primary culture; 2) activated transcription factors within a structurally related family such as p50 and p52 can recognize identical consensus sites, as has been reported (51); 3) the up-regulation of cyclin D1 is mediated through NF{kappa}B in MEC primary culture.

A number of reports have documented an important role for p52 in regulating cyclin D1. In human breast epithelial cells, a p52 homodimer/bcl3 complex was found to bind to the NF{kappa}B site and directly activate the cyclin D1 promoter (41). In untransformed murine mammary cells, RelB/p52 induced cyclin D1 promoter activity (52). Moreover, a RelB/p52 complex rescued a delay in mammary gland ductal branching and an induction of cyclin D1 during early pregnancy, in transgenic mice expressing the I{kappa}B{alpha} super-repressor (53). These same investigators also reported that the anchorage-independent growth of breast tumor cells was blocked through inhibition of RelB and the accompanying suppression of cyclin D1 (53). Our observation that TNF induced the occupancy of p52 and RelB on the cyclin D1 promoter, together with the TNF-stimulated increase in the expression of p52 and cyclin D1 in p50 null mice, suggests that p52 and RelB play more important roles than p50 in cyclin D1 transcription in MEC. Moreover, the insensitivity of p52/RelB to I{kappa}B{alpha} may allow sustained activation of NF{kappa}B (51) and could account for the prolonged effect of TNF on NF{kappa}B-mediated transcription in our MEC model.

Compensation of p52 for p50
NF{kappa}B1/p50 and NF{kappa}B2/p52 are distinct NF{kappa}B members, but are similar in structure, lack transactivation domains, and undergo proteolysis from precursors. They have distinct functions in organogenesis and inflammation, but are redundant for osteoclastogenesis (18) and lymph node formation (54). Functional compensation within the NF{kappa}B family has been demonstrated in various NF{kappa}B null cell lines (55). In particular, Hoffmann et al. (55) found that p52 could compensate for p50 in p50 null fibroblasts, whereas c-Rel could compensate for p65. In addition, TNF-induced expression of some genes, including RANTES and IP-10 was not affected by p50 or p52 deficiency but was only defective in cells lacking both proteins. Similarly, in our present study we found that in p50 null MEC, TNF increased expression of p52, and induced an NF{kappa}B DNA-binding complex containing p52. However, in contrast to NF{kappa}B1/p50 null fibroblasts in which p52 formed a DNA-binding complex with p65, RelB complexed with p52 in p50 null MEC. These data suggest that the compensation between NF{kappa}B proteins is a common but cell type-specific event. This needs to be taken into consideration when studying the function of an individual NF{kappa}B-regulated gene or when developing NF{kappa}B-targeted therapeutics.

Future studies will be necessary to determine whether p50 can compensate for p52 in p52 null MEC, and/or whether TNF-stimulated growth of MEC and the up-regulation of cyclin D1 are prevented in MEC which are deficient in both p50 and p52. These questions are not addressable in breast cell lines, because the majority of human and rodent cell breast cell lines that we have examined are not growth stimulated by TNF, and for most of them, the major TNF-inducible complex is the p65/p50 heterodimer rather than the NF{kappa}B dimers that we and others have identified in tissue samples and primary culture.

In summary, we conclude that NF{kappa}B1/p50 protein is not required for TNF-stimulated growth of MEC nor the up-regulation of cyclin D1. However, the induction by TNF of its DNA-binding activity in MEC from both wild-type rats and mice, as well as the TNF-induced formation of a complex of p50 with its transactivator bcl3, suggest that it may contribute to TNF-stimulated growth, even though it is dispensable. When p50 is absent, p52 and RelB appear to compensate. The present study provides a basis for understanding the mechanism by which TNF stimulates the growth of malignant breast epithelial cells. Endogenous TNF within the tumor environment may enhance tumor development and spread, at least in a subset of patients. With respect to this consideration, studies have been initiated to examine the efficacy of therapies that target TNF in women with breast cancer (56). Understanding the mechanism by which TNF stimulates the growth of mammary tumor cells may help in the development of a new treatment for breast cancer.


   Acknowledgments
 
We thank Dr. Alexander Hoffman (University of California San Diego, La Jolla, CA) for providing lysates from p52 null and wild-type fibroblasts and Dr. Ulrich Siebenlist (National Institutes of Health, Bethesda, MD) for the tissue samples from p52 null mice, which we used to verify antibody specificity. Our gratitude also goes to Sibel McGee for her help with the animal work, to Laura Lee for technical assistance, and to Dr. Gokul Das and his laboratory for their assistance in setting up the ChIP assay. We also thank Dr. Erica Berleth for helpful comments on the manuscript.


   Footnotes
 
Present address for J.Z.: Department of Medical Oncology, Fox Chase Cancer Institute, Philadelphia, Pennsylvania 19111.

This work was supported by National Institutes of Health Grant CA77656 and by the shared resources of the National Cancer Institute Cancer Center Support Grant CA16056.

Disclosure Statement: The authors have nothing to disclose.

First Published Online September 28, 2006

Abbreviations: ChIP, Chromatin immunoprecipitation assay; DAI, DNA affinity immunoblotting; DTT, dithiothreitol; EHS, Engelbreth-Holm-Swarm; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; I{kappa}B, inhibitor of NF{kappa}B; IKK, I{kappa}B kinase; MEC, mammary epithelial cell; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NF{kappa}B, nuclear factor {kappa}B; PMSF, phenylmethylsulfonyl fluoride; RBM, reconstituted basement membrane; SFM, serum-free medium.

Received April 18, 2006.

Accepted for publication September 15, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Varela LM, Ip MM 1996 Tumor necrosis factor-{alpha}: a multifunctional regulator of mammary gland development. Endocrinology 137:4915–4924[Abstract]
  2. Hahm HA, Ip MM 1990 Primary culture of normal rat mammary epithelial cells within a basement membrane matrix. I. Regulation of proliferation by hormones and growth factors. In Vitro Cell Dev Biol 26:791–802[Medline]
  3. Hahm HA, Ip MM, Darcy K, Black JD, Shea WK, Forczek S, Yoshimura M, Oka T 1990 Primary culture of normal rat mammary epithelial cells within a basement membrane matrix. II. Functional differentiation under serum-free conditions. In Vitro Cell Dev Biol 26:803–814[Medline]
  4. Darcy KM, Black JD, Hahm HA, Ip MM 1991 Mammary organoids from immature virgin rats undergo ductal and alveolar morphogenesis when grown within a reconstituted basement membrane. Exp Cell Res 196:49–65[CrossRef][Medline]
  5. Ip MM, Shoemaker SF, Darcy KM 1992 Regulation of rat mammary epithelial cell proliferation and differentiation by tumor necrosis factor {alpha}. Endocrinology 130:2833–2844[Abstract/Free Full Text]
  6. Varela LM, Darcy KM, Ip MM 1997 The epidermal growth factor receptor is not required for tumor necrosis factor-{alpha} action in normal mammary epithelial cells. Endocrinology 138:3891–3900[Abstract/Free Full Text]
  7. Lee PP, Hwang JJ, Murphy G, Ip MM 2000 Functional significance of MMP-9 in tumor necrosis factor-induced proliferation and branching morphogenesis of mammary epithelial cells. Endocrinology 141:3764–3773[Abstract/Free Full Text]
  8. Shea-Eaton WK, Lee PP, Ip MM 2001 Regulation of milk protein gene expression in normal mammary epithelial cells by tumor necrosis factor. Endocrinology 142:2558–2568[Abstract/Free Full Text]
  9. Zhang H, Zhang H, Lee L, Ip MM 2004 The liver-enriched inhibitory protein isoform of CCAAT/enhancer-binding protein ß, but not nuclear factor-{kappa}B, mediates the transcriptional inhibition of ß-casein by tumor necrosis factor-{alpha}. Endocrinology 145:2833–2844[Abstract/Free Full Text]
  10. Varela LM, Stangle-Castor NC, Shoemaker SF, Shea-Eaton WK, Ip MM 2001 TNF{alpha} induces NF{kappa}B/p50 in association with the growth and morphogenesis of normal and transformed rat mammary epithelial cells. J Cell Physiol 188:120–131[CrossRef][Medline]
  11. Hayden MS, Ghosh S 2004 Signaling to NF-{kappa}B. Genes Dev 18:2195–2224[Abstract/Free Full Text]
  12. Beinke S, Ley SC 2004 Functions of NF-{kappa}B1 and NF-{kappa}B2 in immune cell biology. Biochem J 382:393–409[CrossRef][Medline]
  13. Bours V, Franzoso G, Azarenko V, Park S, Kanno T, Brown K, Siebenlist U 1993 The oncoprotein Bcl-3 directly transactivates through {kappa}B motifs via association with DNA-binding p50B homodimers. Cell 72:729–739[CrossRef][Medline]
  14. Nolan GP, Fujita T, Bhatia K, Huppi C, Liou HC, Scott ML, Baltimore D 1993 The bcl-3 proto-oncogene encodes a nuclear I{kappa}B-like molecule that preferentially interacts with NF-{kappa}B p50 and p52 in a phosphorylation-dependent manner. Mol Cell Biol 13:3557–3566[Abstract/Free Full Text]
  15. Yamamoto Y, Gaynor RB 2004 I{kappa}B kinases: key regulators of the NF-{kappa}B pathway. Trends Biochem Sci 29:72–79[CrossRef][Medline]
  16. Sha WC, Liou HC, Tuomanen EI, Baltimore D 1995 Targeted disruption of the p50 subunit of NF-{kappa}B leads to multifocal defects in immune responses. Cell 80:321–330[CrossRef][Medline]
  17. Franzoso G, Carlson L, Poljak L, Shores EW, Epstein S, Leonardi A, Grinberg A, Tran T, Scharton-Kersten T, Anver M, Love P, Brown K, Siebenlist U 1998 Mice deficient in nuclear factor (NF)-{kappa}B/p52 present with defects in humoral responses, germinal center reactions, and splenic microarchitecture. J Exp Med 187:147–159[Abstract/Free Full Text]
  18. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-{kappa}B1 and NF-{kappa}B2. Nat Med 3:1285–1289[CrossRef][Medline]
  19. Gerondakis S, Grossmann M, Nakamura Y, Pohl T, Grumont R 1999 Genetic approaches in mice to understand Rel/NF-{kappa}B and I{kappa}B function: transgenics and knockouts. Oncogene 18:6888–6895[CrossRef][Medline]
  20. Brantley DM, Yull FE, Muraoka RS, Hicks DJ, Cook CM, Kerr LD 2000 Dynamic expression and activity of NF-{kappa}B during post-natal mammary gland morphogenesis. Mech Dev 97:149–155[CrossRef][Medline]
  21. Cao Y, Karin M 2003 NF-{kappa}B in mammary gland development and breast cancer. J Mammary Gland Biol Neoplasia 8:215–223[CrossRef][Medline]
  22. Brantley D, Chen C, Muraoka R, Bushdid P, Bradberry J, Kittrell F, Medina D, Matrisian L, Kerr L, Yull F 2001 Nuclear factor {kappa}b (NF-{kappa}B) regulates proliferation and branching in mouse mammary epithelium. Mol Biol Cell 12:1445–1455[Abstract/Free Full Text]
  23. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet Jr RJ, Sledge GW 1997 Constitutive activation of NF-{kappa}B during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629–3639[Abstract]
  24. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin Jr AS 2000 Selective activation of NF-{kappa}B subunits in human breast cancer: potential roles for NF-{kappa}B2/p52 and for Bcl-3. Oncogene 19:1123–1131[CrossRef][Medline]
  25. Bhat-Nakshatri P, Sweeney CJ, Nakshatri H 2002 Identification of signal transduction pathways involved in constitutive NF-{kappa}B activation in breast cancer cells. Oncogene 21:2066–2078[CrossRef][Medline]
  26. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD 2004 NF-{kappa}B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101:10137–10142[Abstract/Free Full Text]
  27. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC 2005 The NF{kappa}B pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 12(Suppl 1):S37–S46
  28. Romieu-Mourez R, Kim DW, Shin SM, Demicco EG, Landesman-Bollag E, Seldin DC, Cardiff RD, Sonenshein GE 2003 Mouse mammary tumor virus c-rel transgenic mice develop mammary tumors. Mol Cell Biol 23:5738–5754[Abstract/Free Full Text]
  29. Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP, Bours V 1995 Highly-expressed p100/p52 (NFKB2) sequesters other NF-{kappa}B-related proteins in the cytoplasm of human breast cancer cells. Oncogene 11:1835–1841[Medline]
  30. Zhou Y, Eppenberger-Castori S, Marx C, Yau C, Scott GK, Eppenberger U, Benz CC 2005 Activation of nuclear factor-{kappa}B (NF{kappa}B) identifies a high-risk subset of hormone-dependent breast cancers. Int J Biochem Cell Biol 37:1130–1144[CrossRef][Medline]
  31. Ip MM, Darcy KM 1996 Three-dimensional mammary primary culture model systems. J Mammary Gland Biol Neoplasia 1:91–110[CrossRef][Medline]
  32. Darcy KM, Zangani D, Lee P-PH, Ip MM 2000 Isolation and culture of normal rat mammary epithelial cells. In: Ip MM, Asch BB, eds. Methods in mammary gland biology and breast cancer research. New York: Kluwer Academic; 163–193
  33. Brasier AR, Lu M, Hai T, Lu Y, Boldogh I 2001 NF-{kappa}B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-{kappa}B1 residence. J Biol Chem 276:32080–32093[Abstract/Free Full Text]
  34. Liu Y, Asch H, Kulesz-Martin MF 2001 Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting. Cancer Res 61:5402–5406[Abstract/Free Full Text]
  35. Boyd KE, Farnham PJ 1999 Coexamination of site-specific transcription factor binding and promoter activity in living cells. Mol Cell Biol 19:8393–8399[Abstract/Free Full Text]
  36. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M 2000 Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843–852[CrossRef][Medline]
  37. Fujita T, Nolan GP, Liou HC, Scott ML, Baltimore D 1993 The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-{kappa}B p50 homodimers. Genes Dev 7:1354–1363[Abstract/Free Full Text]
  38. Pereira DS, Kushner DB, Ricciardi RP, Graham FL 1996 Testing NF-{kappa}B1–p50 antibody specificity using knockout mice. Oncogene 13:445–446[Medline]
  39. Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin Jr AS 1999 NF-{kappa}B controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 19:5785–5799[Abstract/Free Full Text]
  40. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M 1999 NF-{kappa}B function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19:2690–2698[Abstract/Free Full Text]
  41. Westerheide SD, Mayo MW, Anest V, Hanson JL, Baldwin Jr AS 2001 The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G1 transition. Mol Cell Biol 21:8428–8436[Abstract/Free Full Text]
  42. Joyce D, Bouzahzah B, Fu M, Albanese C, D’Amico M, Steer J, Klein JU, Lee RJ, Segall JE, Westwick JK, Der CJ, Pestell RG 1999 Integration of Rac-dependent regulation of cyclin D1 transcription through a nuclear factor-{kappa}B-dependent pathway. J Biol Chem 274:25245–25249[Abstract/Free Full Text]
  43. Kitazawa S, Kitazawa R, Maeda S 1999 Transcriptional regulation of rat cyclin D1 gene by CpG methylation status in promoter region. J Biol Chem 274:28787–28793[Abstract/Free Full Text]
  44. Yilmaz ZB, Weih DS, Sivakumar V, Weih F 2003 RelB is required for Peyer’s patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J 22:121–130[CrossRef][Medline]
  45. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V 2003 RelB/p50 dimers are differentially regulated by tumor necrosis factor-{alpha} and lymphotoxin-ß receptor activation: critical roles for p100. J Biol Chem 278:23278–23284[Abstract/Free Full Text]
  46. Pratt MA, Bishop TE, White D, Yasvinski G, Menard M, Niu MY, Clarke R 2003 Estrogen withdrawal-induced NF-{kappa}B activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol Cell Biol 23:6887–6900[Abstract/Free Full Text]
  47. Deb S, Amin S, Imir AG, Yilmaz MB, Suzuki T, Sasano H, Bulun SE 2004 Estrogen regulates expression of tumor necrosis factor receptors in breast adipose fibroblasts. J Clin Endocrinol Metab 89:4018–4024[Abstract/Free Full Text]
  48. Bundy DL, McKeithan TW 1997 Diverse effects of BCL3 phosphorylation on its modulation of NF-{kappa}B p52 homodimer binding to DNA. J Biol Chem 272:33132–33139[Abstract/Free Full Text]
  49. Fantl V, Stamp G, Andrews A, Rosewell I, Dickson C 1995 Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes Dev 9:2364–2372[Abstract/Free Full Text]
  50. Sicinski P, Donaher JL, Parker SB, Li T, Fazeli A, Gardner H, Haslam SZ, Bronson RT, Elledge SJ, Weinberg RA 1995 Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82:621–630[CrossRef][Medline]
  51. Saccani S, Pantano S, Natoli G 2003 Modulation of NF-{kappa}B activity by exchange of dimers. Mol Cell 11:1563–1574[CrossRef][Medline]
  52. Rocha S, Martin AM, Meek DW, Perkins ND 2003 p53 Represses cyclin D1 transcription through down regulation of Bcl-3 and inducing increased association of the p52 NF-{kappa}B subunit with histone deacetylase 1. Mol Cell Biol 23:4713–4727[Abstract/Free Full Text]
  53. Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang X, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE 2005 RelB/p52 NF-{kappa}B complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor I{kappa}B-{alpha} expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 25:10136–10147[Abstract/Free Full Text]
  54. Lo JC, Basak S, James ES, Quiambo RS, Kinsella MC, Alegre ML, Weih F, Franzoso G, Hoffmann A, Fu YX 2006 Coordination between NF-{kappa}B family members p50 and p52 is essential for mediating LTßR signals in the development and organization of secondary lymphoid tissues. Blood 107:1048–1055[Abstract/Free Full Text]
  55. Hoffmann A, Leung TH, Baltimore D 2003 Genetic analysis of NF-{kappa}B/Rel transcription factors defines functional specificities. EMBO J 22:5530–5539[CrossRef][Medline]
  56. Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL 2004 A phase II study of etanercept (Enbrel), a tumor necrosis factor {alpha} inhibitor in patients with metastatic breast cancer. Clin Cancer Res 10:6528–6534[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
M. A. Warren, S. F. Shoemaker, D. J. Shealy, W. Bshar, and M. M. Ip
Tumor necrosis factor deficiency inhibits mammary tumorigenesis and a tumor necrosis factor neutralizing antibody decreases mammary tumor growth in neu/erbB2 transgenic mice
Mol. Cancer Ther., September 1, 2009; 8(9): 2655 - 2663.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, J.
Right arrow Articles by Ip, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, J.
Right arrow Articles by Ip, M. M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals